Drug Shows Some Promise for PTCL Sufferers

Peripheral T-cell lymphoma (PTCL) attacks only about ten percent of people diagnosed with non-Hodgkin's lymphoma every year but it’s a very deadly form of lymphoma and one of the most difficult to treat. Furthermore, there are currently no FDA-approved treatments for PTCL.

A recent clinical trial carried out by Allos Therapeutics for the experimental drug pralatrexate showed that of the 115 PTCL patients, 27% responded to the drug while 11% reached full remission. Patients responded to the drug for an average of 9.4 months, substantially longer than anyone expected.

The good results surprised Allos. They intend to seek regulatory approval of pralatrexate, also known as PDX, later this year. The FDA has granted the drug orphan status, and Allos is testing it against other forms of cancer.

Pralatrexate works by disguising itself as a folic acid which a cancerous tumor readily absorbs. Once inside, the drug attacks the tumor.

LymphomaInfo Social